Most Read Articles
Stephen Padilla, 18 Nov 2020
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

Acute autoimmune hepatitis a growing threat in Japan

12 Sep 2020

Acute autoimmune hepatitis (AIH) appears to be increasingly prevalent in Japan, a recent study has found. New strategies for diagnosis are needed to combat an emerging public health threat.

“To the best of our knowledge, this evidence of an increasing trend of acute AIH was the first to be reported worldwide,” researchers said.

They surveyed 138 hospitals that had hepatology specialists, asking for patients who had been newly diagnosed with AIH between 2014 and 2017. Fifty-four centres returned the questionnaires, yielding a total of 796 patients (median age at diagnosis, 63 years) eligible for the present analysis. A parallel group of 1,410 AIH patients from the previous nationwide survey in 2015 was also included.

In both surveys, majority of the patients had been diagnosed within 6 months from the estimated time of disease onset (2018: 79.0 percent; 2015: 77.2 percent; p=0.361). In the latest survey, almost half (43.6 percent; n=336) had moderate disease, while 38.5 percent and 17.9 percent had mild and severe AIH, respectively; no such data were available for the 2015 cohort.

The prevalence rate of acute hepatitis in the 2018 survey was 21.7 percent, which was significantly greater than that in the 2015 group (11.0 percent; p<0.001). Chronic hepatitis, in contrast, was more common in the earlier survey (81.9 percent vs 70.0 percent; p<0.001).

Treatments given included prednisolone, ursodeoxycholic acid, and steroid pulse therapy. From 2014 to 2017, nine patients died of liver-related causes, yielding a rate of 1.1 percent. One patient received a liver transplant.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 18 Nov 2020
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).